Compare WLFC & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLFC | IVA |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1997 | 2020 |
| Metric | WLFC | IVA |
|---|---|---|
| Price | $54.28 | $4.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $160.00 | $16.20 |
| AVG Volume (30 Days) | 224.1K | ★ 644.8K |
| Earning Date | 05-05-2026 | 03-30-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $569,223,000.00 | N/A |
| Revenue This Year | $2.75 | N/A |
| Revenue Next Year | $7.35 | $751.20 |
| P/E Ratio | $22.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $52.13 | $3.35 |
| 52 Week High | $244.62 | $7.98 |
| Indicator | WLFC | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 22.49 | 46.93 |
| Support Level | $53.40 | $4.46 |
| Resistance Level | $74.22 | $4.70 |
| Average True Range (ATR) | 2.35 | 0.16 |
| MACD | 4.36 | -0.02 |
| Stochastic Oscillator | 28.59 | 20.75 |
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.